H epatocellular carcinoma (HCC) is the fifth leading cause of cancer death worldwide, and the majority of patients are Asians [1, 2] . Treatment options for HCC depend on the stage of the disease, co-existing cirrhosis, and the patient's overall condition. While in early stage of cancer, surgical resection or liver transplantation may be curative; however, only about 15% of patients have resectable disease at presentation. The majority of patients present in the advanced disease stage, and hence are considered candidates for non surgical options. Until the late 1990s, there was no worldwide, approved local or systemic therapy for advanced HCC and all available therapies for advanced unresectable and metastatic HCC had limited clinical value, with low response rates, and little impact on the natural history of the disease [3] . It was for the first time that in 2008 a large Phase III trial established the survival benefit of sorafenib in advanced HCC [4] . However, the results remain humble with overall survival benefit of around four months. The need for improvement was therefore well recognized.
HCC is considered to have intrinsic resistance to chemotherapy agents. This is due to increased expression of multidrug resistance transporters and active intracellular metabolism [5] . A large number of controlled and uncontrolled studies performed with different classes of chemotherapeutic agents have yielded low response rates [6] [7] [8] After the success of sorafenib, combination regimens with chemotherapeutic agents came under investigation [9] .
Most HCCs develop in cirrhotic livers with impaired liver function and therefore drug hepatic metabolism and its toxicity in this setting is important while considering any therapeutic trial [10] . Gemcitabine, a pyrimidine analogue, is metabolized intracellularly by nucleoside kinases, and excreted mainly in urine. Earlier studies with gemcitabine in patients with liver impairment and elevated aspartate aminotransferase (AST 2-times the upper limit of normal [ULN]) did not show any increase in toxic effects related to gemcitabine. However, dose reduction was recommended in patients with elevated bilirubin levels (>27 lmol/L) [11] This established a limited hepatic friendly profile of gemcitabine in HCC and the hypothesis was that its combination with sorafenib may be beneficial. Thus, the primary objective of this Phase II study was to evaluate the efficacy and safety of a sorafenib and gemcitabine combination therapy in patients with advanced HCC. ; platelet count >100 · 1000 cells/lL), and life expectancy of at least 12 weeks. Patients treated with anticoagulants (coumadin or heparin) earlier were allowed to participate, provided there was no abnormality in these parameters at screening.
METHODS

Study population
Patients were excluded if they had uncontrolled hypertension, clinically active serious infection (>Grade 2 as per National Cancer InstituteCommon Terminology Criteria v3.0), extra-hepatic metastasis, or history of bleeding diathesis. Pregnant or breastfeeding females, patients with seizure disorder requiring medication (such as steroids or anti-epileptics), patients undergoing renal dialysis, and patients requiring trans-arterial catheter embolization were excluded from the study.
The Independent Ethics Committee or Institutional Review Board at each study site approved the protocol and the study was conducted in accordance with the ethical principles outlined in the Declaration of Helsinki and in accordance with ICH Good Clinical Practice guidelines, applicable regulatory requirements, and in compliance with the respective protocol. All patients provided written informed consent. Safety and toxicity evaluations were completed at baseline and on days 1 and 8 of each cycle before the administration of gemcitabine or at the time of early withdrawal. Interim analysis for efficacy was performed at 8 weeks (after two cycles) and on completion of the 4th cycle.
Study design
Study medication
Patients were treated with sorafenib 400 mg oral twice daily for 16 weeks along with gemcitabine 1000 mg/m 2 , intravenous, administered on days 1 and 8 of a four-week cycle for 16 weeks. At 16 weeks an evaluation was required and patents having stable disease, complete or partial remission were continued on treatment combination until any reason for study withdrawal. Gemcitabine dose reduction of 20% was allowed in patients with underlying cirrhosis liver having increased bilirubin, but not exceeding 27 lmol/L. As the potential dose limiting toxicity for gemcitabine is myelosuppression, its dose reduction by 20% was further allowed in case of clinically significant toxicities (National Cancer Institute-Common Terminology Criteria v3.0) and in case of dose delays due to toxicities for more than seven days.
Study withdrawal
All patients were required to complete four cycles unless there was disease progression, consent withdrawal, or clinically significant toxicities for more than seven days despite corrective measures. Neutrophil growth factors for primary prophylaxis were not allowed except in secondary settings when there were delays due to persisting Grade 2 neutropenia or more, for more than seven days, and on occurrence of a single febrile neutropenic episode. Re-escalation of the study drug was permitted with appropriate prophylaxis in patients who had completely resolved adverse event. Dose modification for sorafenib was not allowed in the absence of any known sorafenib-related toxicities with the exception of thrombocytopenia for which the gemcitabine dose would be modified first. The treatment was discontinued in case of sorafenib-related Grade 3 or 4 toxicities.
Efficacy assessment
The primary efficacy assessment was tumor response which was done in accordance with the Response Evaluation Criteria for Solid Tumors (RECIST 1.0). The investigator performed the tumor measurements at baseline and at 8 weeks or two cycles (interim analysis). For a patient to be regarded as achieving stable disease, a 16-week of documented non-progression was required.
Safety assessment
All drug-related adverse events were analyzed according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 3.0, and all serious adverse events regardless of causal relationship to study drugs were recorded.
Statistical analysis
The data was analyzed using Statistical Package for the Social Sciences (SPSS) computer program. Chisquare test was applied to examine any significant association between tumor response and other categorical variables (Child class, ECOG status, Alpha fetoprotein levels, uni/multicentricity). A p value of < 0.05 was considered significant.
RESULTS
Demographics
The study enrolled 30 Asian patients aged between 26 and 73 years (both ages inclusive) (median age: 55.3 years); the majority were men (77%). Baseline demographics and disease characteristics are shown in Table 1 . Overall, 18 (60%) patients completed all four cycles of treatment; four patients expired, two of whom had gastrointestinal hemorrhage from esophageal varices, and the other two had diseaserelated decline in liver function and hepatic failure. Of the eight patients who were withdrawn from the study, two had progressive disease at interim evaluation on eight-week treatment, and six (33%) had persisting gemcitabine-related Grade 3/4 thrombocytopenia despite corrective measures (including dose adjustments and dose delay for more than 1 week). 
Primary efficacy
Among 18 patients, eight (44%) patients achieved stable disease while two (11%) patients showed partial response. No complete response was observed (Table 2) . There was no significant association found between tumor response and any of the variables: Child-Pugh score (p = 0.260), ECOG performance (p = 0.264), AFP levels (p = 0.64) and uni/multicentricity (p = 0.712).
Safety
The most common (10% patients) treatment-emergent adverse events (TEAEs) were hematological events; gemcitabine-related thrombocytopenia was most common (40%) TEAE and required frequent dose modifications and delays. Six patients were withdrawn from the study due to persisting thrombocytopenia of Grade 2 despite corrective treatment and dose delay for more than seven days. Dose modifications (reduction by 20% of calculated gemcitabine dose) due to thrombocytopenia alone were common: two on the average in all patients who completed all eight doses (four cycles). All patients experienced delay in dose at least once up to seven days due to persisting thrombocytopenia. Blood transfusion was required as corrective measure for anemia in two patients, and platelet transfusion was required in four patients for persisting Grade 3-4 thrombocytopenia. Hand-foot skin reaction (33%) and anorexia (33%) were the most common adverse events due to sorafenib (Table 3) .
DISCUSSION
In the present study, of the 60% patients who completed all four cycles of treatment, 11% had partial response while 44% had stable disease, and the remaining 44% had progressive disease. In contrast, the SHARP trial conducted earlier with sorafenib alone showed 71% of patients with stable disease at the end of the treatment period [4] This may be because of the difference in the baseline characteristics between the two populations. The Asian population enrolled in the present study was much younger (mean age: 55 years) compared with the population in the SHARP study (mean age: 64 years) [12] The population in our study was similar to the Asia-Pacific population studied by Cheng et al. (mean age: 51 years). The tumor load, ECOG status, and Child-Pugh status in our study population were also similar to the study by Cheng et al. [13] . compared with the baseline population characteristics of the SHARP trial [12] The study by Cheng et al., which had patients with advanced HCC and treated with sorafenib alone -in line with the SHARP study -resulted in 54% of patients with stable disease [13] , which is similar to our findings. Thus, in terms of tumor response, no improvement was observed with the combination of sorafenib and gemcitabine in the present study compared to the sorafenib treatment as seen in the Asia-Pacific (Cheng et al.) and the SHARP studies.
Serum AFP response has been related to the prediction of radiological response and survival as an independent prognostic factor [14] There was no relation between tumor response and baseline AFP level in this study. Listed are adverse events, as defined by the National Cancer Institute Common Terminology Criteria (version 3.0).
Most of the TEAEs related to sorafenib observed in this study (hand-foot skin reaction, diarrhea and anorexia) are similar to the adverse effects reported in earlier studies [12, 13] The gemcitabine-related hematological toxicities observed in the present study are also seen in earlier reported studies. Earlier studies with gemcitabine in HCC, used as single agent [15] or in combination with cisplatin or doxorubicin, have shown similar toxicity [16] However, there were frequent dose adjustments, and delays during the treatment due to gemcitabine-related hematological toxicities for almost all the patients at least once in the 16-week treatment. In addition to this, corrective treatments like blood transfusion (two patients) and platelet transfusion (four patients) were needed during the treatment.
Eric Assenat et al. presented the GONEXT study from France in the 2013 meeting of the American Society of Clinical Oncology. Sorafenib plus gemcitabine and oxliplatin (twice weekly) was found to be feasible although subset analysis as to who benefitted most is awaited. Hematological toxicity was common but was not the limiting factor in this study. In our study, all patients had cirrhosis liver: 80% of those with Child-Pugh score A.
The limitation was that this was a non-randomized study, and only 60% of patients were evaluable.
Gemcitabine alone administered in the same dose but on day 1 and day 8 of a four-weekly cycle plus sorafenib was found to be hematologically more toxic.
CONCLUSION
There is no difference between the efficacy of sorafenib and gemcitabine combination therapy and sorafenib alone treatment. However, higher gemcitabinerelated toxicity followed by frequent dose adjustments, delays, and corrective treatment including blood component therapy makes this combination therapy unsuitable for the treatment of advanced HCC.
